Stock Analiz

Entrada Therapeutics, Inc. TRDA

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$5.09Market cap $199M
Open the interactive analysis →

Entrada Therapeutics, Inc. (TRDA) is a healthcare company listed in the US with a market value of about $199M. In the twelve months to September 30, 2026 it had revenue of $4M and net income of -$161M, a net margin of -4058.0%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -15%.

About Entrada Therapeutics

Entrada Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 1 of the last 6 years in our data. Its share count rose by 32% over three years (dilution for shareholders). It spends 560% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S50.1
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-68.4%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-87.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-179.8%
ROIC (5-yr avg.)-14.8%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$4M$25M$211M$129M———
Net income-$161M-$144M$66M-$7M-$95M-$51M-$27M
Free cash flow-$136M-$130M-$45M$134M-$97M-$55M-$28M
EPS (diluted)$-3.84$-3.47$1.68$-0.20$-3.02$-8.16$-24.00
Net margin-4058.0%-565.5%31.1%-5.2%———
ROIC—-34.9%7.6%-0.8%-32.2%-13.5%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Entrada Therapeutics pay a dividend?

Not currently.

Is Entrada Therapeutics a good stock to buy?

We do not give buy or sell advice. Entrada Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.